Management of genitourinary malignancy is likely to demand a large portion of the urologist's time and practice, and the challenge for modern urology is not only in understanding the management of commonly seen genitourinary malignancies but also in identifying significant associations that can be risk factors in the development of malignant tumors.1Many biomarkers have been studied as assessors of outcomes in the development and treatment of malignant diseases, and one of them is the ABO blood group. This evidence concerns the gene ABO and cancer.